Compassionate Use of Dupilumab
Primary Purpose
Bullous Pemphigoid, Pediatric Eosinophilic Esophagitis (EoE), Pediatric Asthma
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Dupilumab
Sponsored by
About this trial
This is an expanded access trial for Bullous Pemphigoid
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT04776694
First Posted
February 25, 2021
Last Updated
July 26, 2022
Sponsor
Regeneron Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT04776694
Brief Title
Compassionate Use of Dupilumab
Study Type
Expanded Access
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
Provide Compassionate Use of Dupilumab
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bullous Pemphigoid, Pediatric Eosinophilic Esophagitis (EoE), Pediatric Asthma, Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Dupilumab
Other Intervention Name(s)
REGN668, DUPIXENT®, SAR231893
10. Eligibility
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Requests for compassionate use must be initiated by a treating physician. Physicians should contact
Phone
844-734-6643
Email
CompassionateUse_Requests@regeneron.com
12. IPD Sharing Statement
Learn more about this trial
Compassionate Use of Dupilumab
We'll reach out to this number within 24 hrs